A Randomised, Double-blind, Placebo-controlled, Single-dose and Multiple-dose, Dose-escalation Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2015
At a glance
- Drugs Monalizumab (Primary) ; Monalizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 09 Mar 2015 Results were presented at at the 13th International Congress on Targeted Anticancer Therapies, according to an Innate Pharma media release.
- 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.